Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

NCT04340362 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Glomerulosclerosis, Focal Segmental

Interventions

DRUG: VX-147

Sponsor

Vertex Pharmaceuticals Incorporated